The 'NewCo' model, which creates a Western company around in-licensed Asian assets, is now leveraging reverse mergers for a fast track to public markets. Slate Medicines' deal with Fulcrum Therapeutics exemplifies this trend, following similar moves by companies like Yarrow and Serapha, shortening the path from inception to public listing.
To target the oncogenic beta-catenin pathway, companies are taking fundamentally different and sometimes contradictory approaches. For example, Parabolus directly blocks the cancer-driving TCF interaction, while Sapiens purposefully avoids it, believing it's key for healthy cell function, highlighting a key scientific debate in the field.
The challenge for global drug development isn't that first-in-human trial timelines are newly slow; it's that China's accelerated pace has created an unprecedented sense of urgency. This competitive pressure is forcing Western companies and regulators to re-evaluate and expedite their own clinical development processes.
Renowned CAR-T expert George Shet is co-founding Boulevard Bio, a company focused on immunology and inflammation (I&I), not cell therapy. This move suggests that deep biological expertise—in this case, B-cell depletion—can be strategically applied across different therapeutic modalities like bispecific and trispecific antibodies, beyond a scientist's original field.
The successful 'NewCo' model, initially focused on in-licensing assets from Asia for Western development, is evolving. Companies like Boulevard Bio now create hybrid entities that combine assets from Asia with those from the U.S. or other global sources, diversifying their pipelines and de-risking their geographic concentration from inception.
After an FDA advisory committee voted against its DMD therapy for a cardiomyopathy indication, Capricor refocused its application on improving limb function. This strategic pivot demonstrates how companies can salvage a regulatory submission by shifting to an endpoint that received more positive feedback during the AdCom process, even if it wasn't the original primary target.